ERGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ERGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ergo Science's Enterprise Value is $7.85 Mil. Ergo Science's EBIT for the trailing twelve months (TTM) ended in Sep. 2006 was $-3.02 Mil. Therefore, Ergo Science's EV-to-EBIT for today is -2.60.
The historical rank and industry rank for Ergo Science's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ergo Science's Enterprise Value for the quarter that ended in Sep. 2006 was $2.63 Mil. Ergo Science's EBIT for the trailing twelve months (TTM) ended in Sep. 2006 was $-3.02 Mil. Ergo Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2006 was -115.09%.
The historical data trend for Ergo Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ergo Science Annual Data | |||||||||||||||||||||
Trend | Dec96 | Dec97 | Dec98 | Dec99 | Dec00 | Dec01 | Dec02 | Dec03 | Dec04 | Dec05 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | 2.82 | - | - | - | -1.11 |
Ergo Science Quarterly Data | ||||||||||||||||||||
Dec01 | Mar02 | Jun02 | Sep02 | Dec02 | Mar03 | Jun03 | Sep03 | Dec03 | Mar04 | Jun04 | Sep04 | Dec04 | Mar05 | Jun05 | Sep05 | Dec05 | Mar06 | Jun06 | Sep06 | |
EV-to-EBIT | Get a 7-Day Free Trial | - | - | - | - | - |
For the Staffing & Employment Services subindustry, Ergo Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Business Services industry and Industrials sector, Ergo Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ergo Science's EV-to-EBIT falls into.
Ergo Science's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 7.850 | / | -3.021 | |
= | -2.60 |
Ergo Science's current Enterprise Value is $7.85 Mil.
Ergo Science's EBIT for the trailing twelve months (TTM) ended in Sep. 2006 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ergo Science (GREY:ERGN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Ergo Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2006 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2006 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2006 ) |
= | -3.021 | / | 2.625 | |
= | -115.09 % |
Ergo Science's Enterprise Value for the quarter that ended in Sep. 2006 was $2.63 Mil.
Ergo Science's EBIT for the trailing twelve months (TTM) ended in Sep. 2006 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ergo Science's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Citigroup Inc | director | 388 GREENWICH STREET, NEW YORK NY 10013 |
Iticorp | director | 399 PARK AVENUE, NEW YORK NY 10043 |
Citicorp Banking Corp | director | ONE PENNS WAY, NEW CASTLE DE 19720 |
Citigroup Holdings Co | director | 336 THE STRAND, LONDON ENGLAND |
Court Square Capital Ltd | director | 399 PARK AVE, NEW YORK NY 10043 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.